Related Experiment Video
Updated: Mar 22, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
22.1K
Persistent bone marrow depression following short-term treatment with temozolomide
Kathrine Vandraas1, Geir Erland Tjønnfjord2, Tom Børge Johannesen1
1Oslo University Hospital, Oslo, Norway.
BMJ Case Reports
|May 1, 2016
Summary
Temozolomide, a glioblastoma treatment, can cause severe bone marrow failure. This case highlights a rare but serious side effect, even with short-term use, requiring extensive blood transfusions.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Temozolomide (TMZ) combined with radiotherapy (RT) is standard care for glioblastoma multiforme.
- While generally safe, TMZ can cause hematological side effects in 1-10% of patients.
Observation:
- A glioblastoma patient developed severe bone marrow failure (BMF) after only three weeks of TMZ treatment.
- The BMF was profound, showing no improvement for 12 months.
Findings:
- This case illustrates an exceptionally severe and prolonged BMF reaction to TMZ.
- The patient required over 100 blood cell transfusions due to the BMF.
Implications:
- Clinicians should be vigilant for rare but severe hematological toxicities like BMF with TMZ.
- This case underscores the need for careful patient monitoring during glioblastoma treatment.
- Further research into predicting and managing TMZ-induced BMF is warranted.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
2.3K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.3K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:56Treatment Resistent Cancers
1.5K
1.5K
01:29Therapeutic Drug Monitoring: Affecting Factors
322
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
322
01:05Long-term Depression
33.7K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.7K